Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd
August 30, 2022
Share
Ruibo (Hangzhou) Pharmaceutical Technology Co., Ltd. announced a capital increase of CNY 30,000,000 on August 31, 2022. The round will include participation from returning investor, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. The transaction has been approved in the 21st Meeting of the company's 7th Directorate and the 15th Meeting of the Company's 7th Supervisory Board.
On December 2, 2022, the company completed the change of business registration of its capital increase, and its registered capital increased from CNY 84,671,532.85 to CNY 89,051,094.89.
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD 
